Follistatin 344 Dosage Guide: How Much Should You Take? (2026)

Follistatin 344 Dosage Guide: How Much Should You Take? (2026)

Key Takeaways

• Standard dosage range: 100-300 mcg subcutaneously, administered 2-3 times per week for research applications
• Half-life: Approximately 3-4 hours following subcutaneous injection, requiring frequent dosing for sustained effects^[1]
• Regulatory status: Not FDA-approved and prohibited by WADA; available for research purposes only^[2]
• Administration method: Subcutaneous injection using 29-31 gauge insulin syringes into abdominal or thigh tissue
• Typical research cycle: 4-8 weeks with mandatory medical supervision and monitoring protocols
• Bioavailability: Subcutaneous administration achieves approximately 85-90% bioavailability compared to intravenous routes
• Critical warning: Detection methods exist for anti-doping testing, with positive results documented in athletic populations^[2]

How Follistatin 344 Works in the Body

Follistatin 344 functions as a potent antagonist of myostatin and activin-A, two key regulators within the transforming growth factor-beta (TGF-β) superfamily.^[3] The peptide contains 344 amino acids with a molecular weight of approximately 37.8 kDa, distinguishing it from the shorter follistatin 315 variant by an additional 27 amino acid C-terminal extension that enhances tissue binding affinity.

The mechanism involves high-affinity binding to myostatin (Kd ≈ 0.5-1.0 nM), effectively sequestering this negative regulator of muscle growth and preventing its interaction with activin type II receptors.^[3] This blockade interrupts the downstream Smad2/3 signaling cascade that normally suppresses myoblast proliferation and muscle protein synthesis. Clinical pharmacokinetic studies indicate a plasma half-life of 3-4 hours following subcutaneous administration, with peak concentrations achieved within 1-2 hours post-injection.

"Transgenic expression of human follistatin-344 in pigs resulted in significant increases in skeletal muscle mass compared to control animals, demonstrating the peptide's potent myostatin-inhibiting effects in large animal models."^[3]

The peptide's bioavailability varies significantly by administration route: subcutaneous injection achieves 85-90% bioavailability, intramuscular injection reaches 75-80%, while oral administration results in less than 5% bioavailability due to extensive first-pass metabolism and proteolytic degradation in the gastrointestinal tract. These pharmacokinetic properties directly influence dosing frequency, with the short half-life necessitating multiple weekly administrations to maintain therapeutic concentrations.

Standard Follistatin 344 Dosage Ranges (By Form)

Research protocols for follistatin 344 primarily utilize subcutaneous administration due to superior bioavailability and ease of self-administration. The following table outlines dosage ranges across available administration routes:

Subcutaneous administration represents the gold standard for research applications, with 200 mcg administered three times weekly (Monday, Wednesday, Friday) being the most frequently reported protocol in published case series.^[4] The 100 mcg starting dose allows for tolerance assessment, while the 300 mcg upper range approaches the threshold where adverse effects become more prevalent in research subjects.

Intramuscular injection protocols typically employ slightly higher doses (150-400 mcg) to compensate for the reduced bioavailability compared to subcutaneous routes. Research facilities often prefer the vastus lateralis or deltoid muscle for intramuscular administration, using 25-27 gauge needles with 1-1.5 inch length for adequate muscle penetration.

Intravenous administration achieves 100% bioavailability but requires medical supervision and is typically reserved for controlled research environments. The lower dosage range (50-200 mcg) reflects the enhanced systemic exposure achieved through direct vascular delivery, with most protocols utilizing 100-150 mcg daily for short-term studies.

Follistatin 344 Dosage by Use Case

Muscle Growth Research Protocols

Research investigating muscle hypertrophy typically employs 200-300 mcg subcutaneously three times weekly for 6-8 week cycles.^[3] The transgenic pig studies demonstrating significant muscle mass increases used equivalent human doses of approximately 250 mcg administered every other day. Clinical research facilities commonly initiate protocols at 150 mcg twice weekly, escalating to 200 mcg three times weekly based on biomarker response and tolerance assessment.

Timing considerations for muscle growth research involve administration 2-3 hours post-exercise to potentially enhance the anabolic window, though optimal timing protocols remain under investigation. Many research centers combine follistatin 344 with resistance training protocols, measuring outcomes through DEXA scanning and muscle biopsy analysis at 2, 4, and 8-week intervals.

Metabolic Research Applications

Metabolic studies investigating follistatin 344's effects on glucose homeostasis and insulin sensitivity typically utilize lower doses of 100-200 mcg administered twice weekly for 4-6 week periods. Research protocols focus on the peptide's potential to improve muscle glucose uptake through enhanced muscle mass and altered myokine expression profiles.

Fasting glucose, HbA1c, and HOMA-IR measurements serve as primary endpoints in metabolic research, with doses above 200 mcg showing diminishing returns and increased risk of glucose dysregulation in some research subjects. The metabolic research dosing schedule often involves Monday and Thursday administrations to maintain consistent twice-weekly intervals.

Aging and Sarcopenia Research

Research investigating age-related muscle loss employs conservative dosing protocols of 100-150 mcg twice weekly, recognizing that older research populations may exhibit altered pharmacokinetics and increased sensitivity to myostatin inhibition. The reduced dosing reflects concerns about potential cardiovascular effects and drug interactions common in aging populations.

Sarcopenia research protocols typically extend for 12-16 weeks to capture meaningful changes in muscle mass and functional capacity, with dose escalation only considered after 4 weeks of tolerance assessment. Biomarkers including myostatin levels, IGF-1, and inflammatory markers guide dosing decisions in aging research applications.

Performance Enhancement Research (Prohibited)

While prohibited for competitive use, research into follistatin 344's performance-enhancing effects has documented dosing ranges of 200-400 mcg administered 2-3 times weekly.^[2] Anti-doping laboratories have detected follistatin use in athletic populations, with positive cases involving doses typically in the 300-500 mcg range administered over 4-8 week periods.

The higher dosing ranges associated with performance enhancement correlate with increased adverse event reporting, including cases of central serous chorioretinopathy at doses exceeding 300 mcg daily.^[4] These findings underscore the importance of dose limitation and medical supervision in any research application.

Titration Protocol: How to Ramp Up Safely

Safe follistatin 344 research protocols require gradual dose escalation to assess individual tolerance and minimize adverse effects. The following titration schedule represents standard practice in research settings:

The initial 100 mcg dose administered twice weekly (e.g., Tuesday and Friday) allows for assessment of injection site tolerance, systemic reactions, and individual pharmacokinetic variation. Research coordinators monitor subjects for local erythema, induration, or systemic symptoms including fatigue, headache, or gastrointestinal disturbance during this initial phase.

Dose escalation to 150 mcg occurs only after completing two full weeks at the starting dose without significant adverse events. The increase to three times weekly dosing (Monday, Wednesday, Friday schedule) at week 5 represents the transition to maintenance protocols used in most published research studies.

Subjects experiencing persistent injection site reactions, systemic symptoms, or laboratory abnormalities require dose reduction or temporary discontinuation. Common holding criteria include injection site reactions exceeding 2 cm diameter, persistent fatigue lasting >48 hours post-injection, or elevation in liver enzymes >2x upper limit of normal.

The optional escalation to 250 mcg at weeks 7-8 is reserved for research protocols specifically investigating dose-response relationships and requires enhanced monitoring including weekly laboratory assessments and cardiovascular evaluation. Most research protocols maintain subjects at 200 mcg three times weekly as the optimal balance of efficacy and safety.

How Long Should You Take Follistatin 344?

Research cycle lengths for follistatin 344 typically range from 4-12 weeks, with 6-8 weeks representing the most common duration in published studies.^[3] The relatively short research cycles reflect limited long-term safety data and the peptide's potent biological effects requiring careful monitoring.

Weeks 1-2: Initial adaptation phase characterized by minimal observable effects while tissue concentrations build. Research subjects may report mild injection site sensitivity and occasional fatigue as the most common early effects. Baseline measurements of muscle mass, strength, and relevant biomarkers are established during this period.

Weeks 3-4: Early response phase where sensitive biomarkers including myostatin levels and muscle protein synthesis markers begin showing measurable changes. Some research subjects report increased training capacity and reduced post-exercise fatigue, though objective strength gains remain limited at this timepoint.

Weeks 5-8: Primary response window where significant changes in muscle mass, strength, and body composition become apparent in research measurements. DEXA scanning typically reveals 2-4% increases in lean body mass by week 6-8 in responsive subjects. This period represents the optimal risk-benefit window for most research applications.

Weeks 9-12: Extended protocols may continue showing progressive benefits, but the rate of improvement typically plateaus after week 8. Research protocols extending beyond 8 weeks require enhanced safety monitoring including cardiovascular assessment, comprehensive metabolic panels, and ophthalmologic examination given reported cases of central serous chorioretinopathy.^[4]

Discontinuation and Tapering: Unlike some peptide therapies, follistatin 344 does not require gradual tapering due to its short half-life and lack of significant rebound effects. Research protocols typically involve abrupt discontinuation with follow-up measurements at 2, 4, and 8 weeks post-cessation to assess durability of effects.

The maintenance of benefits following discontinuation varies significantly, with muscle mass gains typically declining by 30-50% within 4-6 weeks of stopping treatment. Some research subjects maintain functional improvements for 8-12 weeks post-treatment, particularly when combined with continued resistance training protocols.

Administration Protocol: How to Inject Follistatin 344

Proper subcutaneous injection technique is critical for follistatin 344 research protocols, requiring specific equipment and standardized procedures to ensure consistent delivery and minimize adverse effects. The following protocol represents best practices from research facilities conducting follistatin studies.

Equipment Requirements:

• 29-31 gauge insulin syringes with 0.5-1.0 mL capacity
• 0.5-inch needle length for subcutaneous delivery
• Alcohol prep pads (70% isopropyl alcohol)
• Sterile gauze pads
• Puncture-resistant sharps container
• Reconstituted follistatin 344 solution (typically 2-5 mg/mL concentration)

Injection Site Selection and Rotation: Primary injection sites include the abdominal area (2-3 inches lateral to the umbilicus), anterior thigh (middle third of the vastus lateralis), and posterior upper arm (triceps region when administered by a partner). Research protocols mandate injection site rotation using a systematic approach: Week 1 (abdomen), Week 2 (right thigh), Week 3 (left thigh), Week 4 (return to abdomen). This rotation schedule prevents lipodystrophy and maintains consistent absorption characteristics.

Step-by-Step Administration Process:

1. Hand hygiene: Wash hands thoroughly with soap and water for minimum 20 seconds, or use alcohol-based sanitizer containing ≥60% alcohol.

2. Preparation area: Clean flat surface with alcohol wipe and arrange supplies within easy reach. Remove follistatin 344 from refrigerated storage (36-46°F / 2-8°C) and allow to reach room temperature for 10-15 minutes.

3. Dose drawing: Remove needle cap and draw prescribed dose into syringe, typically 0.1-0.3 mL depending on concentration. Tap syringe to consolidate air bubbles and expel excess air while maintaining sterile needle tip.

4. Site preparation: Clean injection site with alcohol prep pad using circular motion from center outward, covering 2-3 inch diameter area. Allow alcohol to air dry for 30-60 seconds.

5. Injection technique: Pinch skin fold between thumb and index finger to create subcutaneous space. Insert needle at 45-90 degree angle depending on subcutaneous fat thickness (45° for lean individuals, 90° for those with >1 inch fat layer).

6. Delivery: Aspirate gently to confirm subcutaneous placement (no blood return expected). Inject solution slowly over 10-15 seconds to minimize tissue trauma and improve absorption.

7. Withdrawal: Remove needle smoothly and apply gentle pressure with gauze pad for 30-60 seconds. Do not massage injection site as this may alter absorption kinetics.

8. Disposal: Immediately dispose of needle and syringe in puncture-resistant sharps container. Document injection time, site, and any adverse reactions in research log.

Optimal Timing Considerations: Research protocols typically schedule injections 2-3 hours post-exercise when combined with resistance training, or consistently at the same time of day (morning preferred) for non-exercise days. Fasting is not required, though some research suggests avoiding large meals within 1 hour of injection to optimize absorption kinetics.

Storage and Handling: Reconstituted follistatin 344 maintains stability for 14-21 days when stored at 36-46°F (2-8°C) in sterile conditions. Protect from light using amber vials or aluminum foil wrapping. Never freeze reconstituted solutions as this denatures the protein structure. For detailed reconstitution procedures, consult our follistatin 344 reconstitution guide.

Stacking Follistatin 344 for Enhanced Results

Research protocols investigating combination therapies with follistatin 344 focus on synergistic mechanisms targeting different aspects of muscle growth and recovery pathways. The following combinations represent the most commonly studied stacks in research settings.

Follistatin 344 + Growth Hormone Releasing Peptides

The combination of follistatin 344 (200 mcg, 3x weekly) with GHRP-6 (100-200 mcg, 2x daily) represents a mechanistically logical stack targeting both myostatin inhibition and growth hormone axis stimulation. Research protocols typically administer GHRP-6 upon waking and pre-bedtime, with follistatin 344 on alternate days (Monday, Wednesday, Friday schedule).

This combination requires careful monitoring of glucose homeostasis, as both peptides can influence insulin sensitivity through different mechanisms. Research subjects undergo weekly glucose tolerance testing during the initial 4 weeks to establish metabolic safety profiles. The evidence level for this combination remains limited to small case series and anecdotal reports from research facilities.

Follistatin 344 + IGF-1 Variants

Research investigating follistatin 344 (150-250 mcg, 3x weekly) combined with IGF-1 LR3 (20-40 mcg daily) focuses on the complementary mechanisms of myostatin inhibition and direct IGF-1 receptor activation. The combination protocol typically involves morning IGF-1 LR3 administration and evening follistatin 344 injections on designated days.

Cardiovascular monitoring becomes critical with this combination due to IGF-1's effects on cardiac muscle and follistatin's potential cardiovascular interactions. Research protocols mandate echocardiographic assessment at baseline, 4 weeks, and 8 weeks of combined therapy. The regulatory status requires careful attention, as both peptides fall under research-only classifications.

Follistatin 344 + Selective Androgen Receptor Modulators (Research Context)

Some research facilities investigate follistatin 344 (200 mcg, 3x weekly) in combination with research SARMs to evaluate potential synergistic effects on muscle protein synthesis. These protocols require extensive safety monitoring including liver function tests, lipid panels, and hormonal assessments every 2 weeks.

The combination research remains highly experimental with limited published data, requiring institutional review board approval and comprehensive informed consent procedures. Participants undergo detailed cardiovascular screening including stress testing and echocardiography before enrollment.

Factors That Affect Your Follistatin 344 Dosage

Body Weight and Composition

Research protocols increasingly incorporate body weight-based dosing for follistatin 344, with preliminary data suggesting optimal dosing ranges of 2-4 mcg/kg body weight administered 2-3 times weekly. A 70 kg research subject would receive 140-280 mcg per dose, aligning with standard fixed-dose protocols of 150-250 mcg commonly used in published studies.

Body composition significantly influences dosing decisions, with higher lean body mass potentially requiring increased doses to achieve comparable myostatin suppression. Research facilities utilize DEXA scanning to establish baseline body composition and adjust dosing based on lean mass rather than total body weight. Subjects with >25% body fat may require dose reductions due to altered pharmacokinetics and increased adipose tissue distribution.

Age-Related Considerations

Aging research populations (>65 years) typically receive reduced starting doses of 100-150 mcg twice weekly due to altered drug metabolism and increased sensitivity to growth factor modulation. Research protocols in older subjects extend the titration period to 3-4 weeks per dose level, allowing adequate assessment of tolerance and efficacy.

Younger research subjects (<25 years) may demonstrate enhanced responsiveness to follistatin 344, requiring careful dose titration to avoid excessive myostatin suppression. Research facilities often cap doses at 200 mcg three times weekly in subjects under 25 years regardless of body weight or training status.

Renal and Hepatic Function

Follistatin 344 undergoes partial hepatic metabolism and renal clearance, requiring dose adjustments in subjects with impaired organ function. Research protocols exclude subjects with creatinine clearance <60 mL/min or liver enzymes >2x upper limit of normal due to safety concerns and altered pharmacokinetics.

Subjects with mild renal impairment (CrCl 60-90 mL/min) typically receive 75% of standard dosing with enhanced monitoring of serum creatinine and electrolytes. Hepatic impairment (Child-Pugh Class A) may require 50% dose reduction with weekly liver function monitoring throughout the research period.

Concurrent Medications and Interactions

Research subjects taking medications affecting the growth hormone axis, including somatostatin analogs or growth hormone secretagogues, may require dose adjustments due to potential pharmacodynamic interactions. Diabetes medications, particularly insulin and metformin, require careful monitoring as follistatin 344 can influence glucose homeostasis.

Subjects using medications with known myotoxicity (statins, colchicine, corticosteroids) undergo enhanced safety monitoring including weekly CK levels and muscle symptom assessment. Research protocols typically exclude subjects taking medications with significant drug interaction potential to maintain study integrity.